PRKAA2 and lung carcinoma: This study identifies PHF2 as an important downstream effector of AMPK that inhibits lung cancer metastasis, highlighting PHF2-S655 phosphorylation as the potential biomarker in lung cancer metastasis and promoting the clinical application of metformin into suppressing tumorigenesis and development.